Related Experiment Video

Updated: Jun 13, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Adenosine A2A receptor expression in peripheral blood mononuclear cells of patients with mild cognitive impairment

Beatrice Arosio1, Chiara Viazzoli, Luigina Mastronardi

  • 1Department of Internal Medicine, Università degli Studi di Milano, Geriatric Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy. beatrice.arosio@unimi.it

Journal of Alzheimer'S Disease : JAD
|April 24, 2010
PubMed

Insights

Adenosine A2A receptor (A2AR) expression in blood cells increases with cognitive decline severity. This may help differentiate subtypes of mild cognitive impairment (MCI) and Alzheimer's disease (AD).

Area of Science:

  • Neuroimmunology
  • Biomarkers for Cognitive Decline

Background:

  • Adenosine signaling via adenosine A2A receptors (A2AR) modulates immune responses.
  • Cognitive decline, including mild cognitive impairment (MCI) and Alzheimer's disease (AD), is associated with complex pathophysiological changes.

Purpose of the Study:

  • To investigate adenosine A2A receptor (A2AR) expression in blood mononuclear cells (PBMCs) from individuals with MCI and AD.
  • To determine if A2AR expression can differentiate between various stages and subtypes of cognitive impairment.

Main Methods:

  • Quantitative analysis of A2AR mRNA levels and receptor density in PBMCs.
  • Comparison of A2AR expression across control, multiple cognitive domain MCI (mcd-MCI), amnestic MCI (a-MCI), and Alzheimer's disease (AD) groups.

Main Results:

  • A significant linear increase in A2AR mRNA and receptor density was observed from mcd-MCI to a-MCI, progressing through AD and controls.
  • No significant difference in A2AR expression was found between Alzheimer's disease patients and controls.

Conclusions:

  • PBMC A2AR expression levels show a graded increase with cognitive decline severity.
  • A2AR expression in PBMCs may serve as a potential biomarker to distinguish between a-MCI and mcd-MCI.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...